397862-45-2

Upstream product

• 397862-44-1 2-(Methylsulfanyl)-6-(3,5-Dimethoxyphenyl)-8-Ethyl-8H-Pyrido[2,3-d]-Pyrimidine-7-One 
• 1634-04-4 tert-butyl methyl ether 
• 113548-13-3 N-(benzenesulfonyl)-3-phenyloxaziridine 

Downstream Products

• 398517-58-3 6-(3,5-Dimethoxy-phenyl)-2-(2-chloro-pyridin-4-ylamino)-8-ethyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 398517-57-2 6-(3,5-Dimethoxy-phenyl)-2-(2,6-dimethyl-pyridin-4-ylamino)-8-ethyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 398517-56-1 6-(3,5-Dimethoxy-phenyl)-8-ethyl-2-(2-methyl-pyridin-4-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one 
• 398517-59-4 6-(3,5-Dimethoxy-phenyl)-2-(2,6-dimethoxy-pyridin-4-ylamino)-8-ethyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 397862-46-3 2-(4-imino-4H-pyridin-1-yl)-6-(3,5-dimethoxyphenyl)-8-ethyl-8H-pyrido[2,3-d]pyrimidin-7-one hydrochloride 

Relevant academic research and scientific papers

2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimdin-7-ones

This invention provides antiangiogenic compounds of the Formula (I), which are useful for treating diseases, resulting from uncontrolled cellular proliferation such as cancer, atherosclerosis, rheumatoid arthritis, and psoriasis. 1

Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones

Process for preparing 2-pyridylamino-pyrido[2,3-d]pyrimidines of Formula (II) wherein Ar is aryl, R′ and R″ are hydrogen, alkyl, alkoxy, or phenyl, and R2 is alkyl.